Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the functional mechanism of NEAT1/let-7b-IGF-1R axis in HCC.
|
31819522 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR-133a to regulate IGF-1R expression.
|
31207081 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1R might be a potential prognostic biomarker for HCC (hazard ratio [HR] = 1.912, 95% confidence interval [CI]: 1.023-3.572, P = .042).The IGF-1R expression level is upregulated in HCC tissues and may act as a prognostic biomarker for the disease.
|
31689787 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the miR-497-5p/IGF1 axis might serve as a novel therapeutic target in patients with HCC.
|
31441605 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we conducted this research to examine the therapeutic effects of nicotinamide against hepatocellular carcinoma (HCC) both in vivo and in vitro through affecting IGF-1 and the balance between PKB and Nrf2.
|
30784932 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum IGF-1 levels were significantly lower in patients with HCC in cirrhosis compared with non-cirrhotic HCC (p < 0.01).
|
30064393 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In epidemiologic and clinicopathological studies on chronic liver disease (CLD), lowered serum levels, decreased tissue expression of IGF1, elevated production of IGF1R and variable IGF2 expression has been noted, from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage.
|
29702590 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin.
|
29989646 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In multivariate models comparing the first, second, and third quartiles with the fourth quartile of IGF-1, the levels of IGF-1 in Q1 and Q2 were associated with HCC recurrence, with an increased risk of 216% [hazard ratios (HR) = 3.16 (95% CI: 1.79-4.28)] and 106% [3.02 (1.36-3.11)].
|
29638204 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Such an effect may contribute to the development of HBV-mediated HCC by increasing pro-survival and anti-apoptotic IGF-1 effects.
|
29981339 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effects of the IGF1-R antagonists GSK1838705A and OSI-906 on HCC cell migration inhibition after Sorafenib and/or VK1 administration, individually or in combination, were evaluated.
|
29470830 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The pathophysiology underlying development of hepatocellular carcinoma in this context is complex and is likely to involve increased proinflammatory mediators, oxidative stress, JNK-1 activation, increased IGF-1 activity, altered gut microbiota and immunomodulation.
|
28290049 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients.
|
28747084 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, IGF-1 induces EMT of HCC via Stat5 signaling pathway.
|
29340101 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-592 targets IGF-1R to suppress cellular proliferation, migration and invasion in hepatocellular carcinoma.
|
28529580 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of the present study demonstrated that miR‑187 acted as a tumor suppressor in HCC progression via direct targeting of IGF‑1R. miR‑187 may therefore exhibit the potential to act as a novel and therapeutic target for HCC treatment in the future.
|
28627639 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IGF1/IGFBP3 molar ratio was not significantly associated with the risk of HCC (OR, 1.311; 95% CI, 0.761-2.260).
|
29113370 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to validate the new IGF-CTP classification system as a prognostic maker for patients with hepatocellular carcinoma (HCC) in a hepatitis B virus endemic area.
|
28107416 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, treatment of hepatoma cells with IGF-I re-distributes GRP78 from endoplasmic reticulum (ER) to cell surface and promotes its physical interaction with IGF-IR.
|
28389416 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, this study highlights a potential role of IGF-1 in modulating cytolytic potential of NK cells of HCC patients. miR-486-5p acts in a cell-specific manner, differentially modulating IGF-1 expression in NK cells and their target hepatocytes with a contemporary inhibitory impact on HCC progression.
|
27388576 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IGF1 is a hub gene that is mostly upregulated in HCC and it is an important player in the p53 signaling pathway.
|
28051262 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these results suggest that GRK2 may inhibit IGF1-induced HCC cell growth and migration through downregulation of EGR1 and indicate that enforced GRK2 may offer a potential therapeutic approach against HCC.
|
26936374 |
2016 |
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The antibody xentuzumab blocked phosphorylation of IGF1 receptor in HCC cell lines and reduced their proliferation and colony formation.
|
27614046 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we report a novel insulin-like growth factor 1 (IGF1) pathway that mediates de novo DNA methylation and TSG (such as DLC1 and CHD5) silencing by upregulation of the DNA methyltransferase 1 (DNMT1) via an AKT/β-transducin repeat-containing protein (βTrCP)-mediated ubiquitin-proteasome pathway in HCC.
|
25420499 |
2015 |